Age-related macular degeneration market across 7MM set to reach $27.5 bn in 2031: GlobalData
Therapies with longer treatment intervals are a dominant trend in the AMD pipeline
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Eylea
Biocon Biologics gets positive CHMP opinion for YESAFILI, biosimilar Aflibercept
YESAFILI is intended for the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema…
Bayer, Arogya Finance join hands for Eylea Easy Pay Program in India
Eylea or Aflibercept solution is indicated for the treatment of diabetic macular oedema (DME) and wet age-related macular…
Bayer gets DCGI nod for intravitreal aflibercept injection, Eylea to treat diabetic macular edema
Intravitreal Aflibercept is administered via injection directly in the area of swelling in the eye